|Other Names||Peptidyl-prolyl cis-trans isomerase F, mitochondrial, PPIase F, Cyclophilin D, CyP-D, CypD, Cyclophilin F, Mitochondrial cyclophilin, CyP-M, Rotamase F, PPIF, CYP3|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||PPIases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides. Involved in regulation of the mitochondrial permeability transition pore (mPTP). It is proposed that its association with the mPTP is masking a binding site for inhibiting inorganic phosphate (Pi) and promotes the open probability of the mPTP leading to apoptosis or necrosis; the requirement of the PPIase activity for this function is debated. In cooperation with mitochondrial TP53 is involved in activating oxidative stress- induced necrosis. Involved in modulation of mitochondrial membrane F(1)F(0) ATP synthase activity and regulation of mitochondrial matrix adenine nucleotide levels. Has anti-apoptotic activity independently of mPTP and in cooperation with BCL2 inhibits cytochrome c-dependent apoptosis.|
|Cellular Location||Mitochondrion matrix|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
PPIF is a member of thepeptidyl-prolyl cis-trans isomerase (PPIase) family. PPIasescatalyze the cis-trans isomerization of proline imidic peptidebonds in oligopeptides and accelerate the folding of proteins. Thisprotein is part of the mitochondrial permeability transition porein the inner mitochondrial membrane. Activation of this pore isthought to be involved in the induction of apoptotic and necroticcell death.
Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :He, Y., et al. Invest. Ophthalmol. Vis. Sci. 49(11):4912-4922(2008)Lamesch, P., et al. Genomics 89(3):307-315(2007)Lin, D.T., et al. J. Biol. Chem. 277(34):31134-31141(2002)Bowles, K.R., et al. Genomics 67(2):109-127(2000)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.